Mallinckrodt plc (MNK) Stock

About Mallinckrodt plc

Mallinckrodt plc operates as a global pharmaceutical company, engaged in the development, manufacturing, marketing, and distribution of specialized medical products and therapies. Its extensive reach covers the United States, Europe, the Middle East, Africa, and various other international markets. The firm's business operations are segmented into two core divisions: Specialty Brands and Specialty Generics. Under its Specialty Brands arm, Mallinckrodt offers a range of pharmaceuticals for autoimmune and rare diseases, spanning therapeutic areas such as neurology, rheumatology, nephrology, ophthalmology, pulmonology, and oncology. The branded portfolio also encompasses immunotherapy solutions, critical care treatments for neonatal respiratory conditions, pain management drugs, cultured skin substitutes, and gastrointestinal remedies. Key branded products include Acthar Gel, a corticotropin injection prescribed for conditions like rheumatoid arthritis, infantile spasms, and multiple sclerosis; INOmax, a vasodilator used to enhance oxygenation and lessen the need for extracorporeal membrane oxygenation; the Therakos photopheresis platform for immunotherapy; Amitiza, a treatment for constipation; and StrataGraft, designed for adults with deep partial-thickness burns. In its development pipeline, Mallinckrodt is advancing Terlipressin for hepatorenal syndrome and SLN 501, a ribonucleic acid silencing therapeutic. Additionally, through its Specialty Generics segment, the company supplies specialized generic medications and active pharmaceutical ingredients (APIs). Mallinckrodt's branded offerings are marketed to a diverse array of healthcare professionals and institutions, including physicians, respiratory therapists, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. The company has also forged a strategic collaboration with Silence Therapeutics plc to develop and commercialize ribonucleic acid interference (RNAi) drug targets. Established in 1867, Mallinckrodt plc maintains its headquarters in Dublin, Ireland.

Mallinckrodt plc is headquartered in IE.

Mallinckrodt plc (MNK) stock trades at $0.34 with a market capitalization of $4.52M. The stock is valued at a price-to-earnings (P/E) ratio of -0.02, price-to-book of 0.01, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.30 and $16.00, and currently trades 97.9% below its 52-week high.

On profitability, Mallinckrodt plc generates a return on equity (ROE) of -26.10%, return on capital employed of -11.70%, an operating margin of -38.28%, a net profit margin of -38.90%.

Official website: www.mallinckrodt.com